Form 4: Arcus Biosciences GC Sells Shares for Tax Obligations

Arcus Biosciences General Counsel Carolyn C. Tang sold shares totaling 14,468 to cover tax withholding obligations related to RSU vesting.

Summary

• General Counsel Carolyn C. Tang of Arcus Biosciences, Inc. reported two non-discretionary sales of common stock.
• On December 16, 2025, 7,658 shares were sold at a weighted average price of $21.8843 per share.
• On December 17, 2025, an additional 6,810 shares were sold at a weighted average price of $22.1595 per share.
• These sales were executed automatically by the issuer to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
• The sales were not discretionary trades by Ms. Tang, but rather pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025.
• Following these transactions, Ms. Tang beneficially owns 124,734 shares of Arcus Biosciences common stock, which includes unvested RSU grants and 1 share purchased via the Employee Stock Purchase Plan on November 30, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While shares were sold, it was a non-discretionary transaction for tax purposes, which is a routine event and not indicative of a lack of confidence. The executive still holds a substantial number of shares.

Positives

• The sales were non-discretionary, indicating they were not a reflection of the insider's view on the company's future performance but rather a standard tax-related event.
• The reporting person still holds a significant number of shares (124,734), including unvested RSUs, aligning her interests with shareholders.

Negatives

• The sale of shares, even for tax purposes, reduces the direct ownership stake of a key executive.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine, non-discretionary tax-related sales. The executive's continued significant holding aligns interests.
• Employees: The equity administration policy provides a clear framework for managing RSU vesting and associated tax obligations.

Key Dates

Recommendation

The reported transactions are routine, non-discretionary sales by an insider to cover tax obligations upon RSU vesting. Such transactions do not typically signal a change in the company's fundamentals or the insider's confidence. The executive retains a substantial equity stake. Therefore, this filing alone does not warrant a change in investment recommendation; a 'hold' stance is appropriate, pending further fundamental analysis.

Keywords

Arcus Biosciences, RCUS, Form 4, Insider Trading, Stock Sale, Tax Withholding, RSU Vesting, Carolyn Tang, General Counsel, Equity Administration Policy